Skip to main navigation Skip to search Skip to main content

Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease

  • Antoni Camins
  • , Miren Ettcheto
  • , Oriol Busquets
  • , Patricia R. Manzine
  • , Rubén Dario Castro-Torres
  • , Carlos Beas-Zarate
  • , Ester Verdaguer
  • , Francesc X. Sureda
  • , Monica Bulló
  • , Jordi Olloquequi
  • , Carme Auladell
  • , Jaume Folch

Research output: Contribution to journal › Article › peer-review

Original languageEnglish (US)
Pages (from-to)93-97
Number of pages5
JournalExpert Opinion on Investigational Drugs
Volume28
Issue number1
DOIs
StatePublished - Jan 2 2019
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alzheimer’s disease
  • glucagon
  • glucagon-like peptide
  • glucose-dependent insulinotropic peptide
  • type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this